Mothers with MS help answer critical breastfeeding safety question

NCT ID NCT06444113

Recruiting now Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study aims to measure how much of the multiple sclerosis (MS) medication ofatumumab passes into breast milk. It will enroll 20 breastfeeding mothers with relapsing MS who are starting or restarting this treatment after giving birth. Researchers will collect milk and blood samples over several months to understand the drug's levels and assess safety for both mother and baby.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-••••

Locations

Brigham and Womens Hospital
ACTIVE_NOT_RECRUITING

Brookline, Massachusetts, 02445, United States
Caribbean Center for Clinical Research, Inc
RECRUITING

Guaynabo, 00968, Puerto Rico

Contact Phone: •••-•••-••••
Duke Neurology
RECRUITING

Durham, North Carolina, 27110, United States

Contact Email: •••••@•••••

Contact
Northwestern Medicine Northwestern University
ACTIVE_NOT_RECRUITING

Winfield, Illinois, 60190, United States
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Munich, Bavaria, 81377, Germany
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Bochum, 44791, Germany
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Hamburg, 22179, Germany
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Tübingen, 72076, Germany
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Foggia, FG, 71122, Italy
Novartis Investigative Site
WITHDRAWN

Roma, RM, 00133, Italy
Novartis Investigative Site
WITHDRAWN

Torino, TO, 10126, Italy
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Bialystok, 15 276, Poland
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

Kielce, 25 726, Poland
Novartis Investigative Site
WITHDRAWN

Krakow, 31 531, Poland
Novartis Investigative Site
WITHDRAWN

Rzeszów, 35-323, Poland
Novartis Investigative Site
WITHDRAWN

Zabrze, 41-800, Poland
Novartis Investigative Site
RECRUITING

Cambridge, CB2 0QQ, United Kingdom
Novartis Investigative Site
ACTIVE_NOT_RECRUITING

London, NW1 2BU, United Kingdom
Novartis Investigative Site
RECRUITING

Oxford, OX3 9DU, United Kingdom
Novartis Investigative Site
RECRUITING

Salford, M6 8HD, United Kingdom
UC Health Neuroscience Ctr
COMPLETED

Aurora, Colorado, 80045, United States
UCSF
ACTIVE_NOT_RECRUITING

San Francisco, California, 94115, United States

Conditions

Explore the condition pages connected to this study.

MULTIPLE SCLEROSIS